Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04601233 (ClinicalTrials.gov)	December 2021	2/10/2020	Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis	Testosterone TReatment for Erectile Dysfunction in Male Multiple Sclerosis Patients With Low Testosterone (TTRED-MS Study)	Multiple Sclerosis;Erectile Dysfunction;Testosterone Deficiency	Drug: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector	Tulane University	Louisiana State University Health Sciences Center in New Orleans;Antares Pharma Inc.	Not yet recruiting	18 Years	N/A	Male	20	Phase 4	United States
2	NCT03910738 (ClinicalTrials.gov)	October 29, 2019	1/4/2019	TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis	TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Nebido ® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection;Drug: Placebo 4 mL Solution for Injection;Procedure: MRI;Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities;Behavioral: Assessment of disability	University Hospital, Strasbourg, France	Bayer;Fédération Hospitalo-Universitaire NEUROGENYCS	Recruiting	18 Years	55 Years	Male	40	Phase 2	France
3	NCT03000127 (ClinicalTrials.gov)	July 1, 2018	17/12/2016	Testosterone for Fatigue in Men With MS	A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis	Multiple Sclerosis	Drug: AndroGel 1 % Topical Gel;Drug: Placebos	University of California, Los Angeles	Washington University School of Medicine	Withdrawn	18 Years	60 Years	Male	0	Phase 2	United States
4	NCT02317263 (ClinicalTrials.gov)	December 2014	3/12/2014	A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis		Multiple Sclerosis	Drug: testosterone;Drug: placebo gel	University of California, Los Angeles	NULL	Withdrawn	18 Years	60 Years	Male	0	Phase 2	NULL
5	NCT01516554 (ClinicalTrials.gov)	February 2012	19/1/2012	Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients	A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients	Multiple Sclerosis;Fatigue	Drug: Testosterone undecanoate;Drug: placebo	Health Sciences Centre, Winnipeg, Manitoba	University of Manitoba;Consortium of Multiple Sclerosis Centers;Manitoba Medical Service Foundation	Terminated	18 Years	65 Years	Male	3	Phase 2	Canada
6	NCT00405353 (ClinicalTrials.gov)	April 2002	28/11/2006	Testosterone Treatment for Multiple Sclerosis	Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial	Multiple Sclerosis	Drug: Androgel 10 grams of gel containing 100 mg of testosterone	University of California, Los Angeles	National Multiple Sclerosis Society	Completed	18 Years	65 Years	Male	10	Phase 1/Phase 2	United States